MX2022011489A - Metodo para producir agentes antiinflamatorios/anticatabolicos mejorados a partir de fluido fisiologico autologo. - Google Patents
Metodo para producir agentes antiinflamatorios/anticatabolicos mejorados a partir de fluido fisiologico autologo.Info
- Publication number
- MX2022011489A MX2022011489A MX2022011489A MX2022011489A MX2022011489A MX 2022011489 A MX2022011489 A MX 2022011489A MX 2022011489 A MX2022011489 A MX 2022011489A MX 2022011489 A MX2022011489 A MX 2022011489A MX 2022011489 A MX2022011489 A MX 2022011489A
- Authority
- MX
- Mexico
- Prior art keywords
- inflammatory
- autologous
- chronic
- physiological fluid
- blood
- Prior art date
Links
- 230000003160 anti-catabolic effect Effects 0.000 title abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 title abstract 2
- 239000012530 fluid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 230000001684 chronic effect Effects 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000008280 blood Substances 0.000 abstract 2
- 210000004369 blood Anatomy 0.000 abstract 2
- 208000000491 Tendinopathy Diseases 0.000 abstract 1
- 208000023835 Tendon disease Diseases 0.000 abstract 1
- 230000001413 cellular effect Effects 0.000 abstract 1
- 210000002808 connective tissue Anatomy 0.000 abstract 1
- 230000003412 degenerative effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 239000001509 sodium citrate Substances 0.000 abstract 1
- 239000006228 supernatant Substances 0.000 abstract 1
- 208000013515 tendinosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/19—Platelets; Megacaryocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2006—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Se proporciona un método para producir una composición antiinflamatoria/anticatabólica autóloga útil en el tratamiento de un mamífero que padece tejidos conectivos dañados y/o lesionados, tendinosis crónica, desgarres musculares crónicos, afecciones articulares degenerativas crónicas y/o trastornos inflamatorios de la piel; el método comprende los siguientes pasos: entregar una sangre recolectada del mamífero a un tubo; almacenar la sangre en presencia de citrato de sodio a una temperatura de aproximadamente 20 °C a aproximadamente 40 °C durante al menos aproximadamente 3.5 horas; centrifugar la sangre para separar la sangre en un componente sobrenadante y una fracción celular; y recoger el componente sobrenadante.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3076046A CA3076046A1 (en) | 2020-03-17 | 2020-03-17 | Method for producing enhanced anti-inflammatory/anti-catabolic agents from autologous physiological fluid with shortened incubation time |
| PCT/CA2021/050351 WO2021184116A1 (en) | 2020-03-17 | 2021-03-16 | Method for producing enhanced anti-inflammatory/ anti-catabolic agents from autologous physiological fluid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022011489A true MX2022011489A (es) | 2022-10-07 |
Family
ID=77745891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022011489A MX2022011489A (es) | 2020-03-17 | 2021-03-16 | Metodo para producir agentes antiinflamatorios/anticatabolicos mejorados a partir de fluido fisiologico autologo. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230146680A1 (es) |
| EP (1) | EP4121067A4 (es) |
| JP (1) | JP2023518085A (es) |
| CN (1) | CN115297871A (es) |
| AU (1) | AU2021238506A1 (es) |
| CA (2) | CA3076046A1 (es) |
| IL (1) | IL296558A (es) |
| MX (1) | MX2022011489A (es) |
| WO (1) | WO2021184116A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3106197A1 (en) * | 2021-01-20 | 2022-07-20 | Antnor Limited | Method for producing blood plasma product useful in the treatment of viral infections characterized by an uncontrolled release of proinflammatory cytokines |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19903876B4 (de) * | 1999-02-01 | 2006-09-28 | Orthogen Gentechnologie Gmbh | Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten |
| CA2866480A1 (en) * | 2014-09-30 | 2016-03-30 | Antnor Limited | Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid |
-
2020
- 2020-03-17 CA CA3076046A patent/CA3076046A1/en not_active Abandoned
-
2021
- 2021-03-16 JP JP2022556532A patent/JP2023518085A/ja active Pending
- 2021-03-16 EP EP21771125.8A patent/EP4121067A4/en active Pending
- 2021-03-16 CN CN202180022389.8A patent/CN115297871A/zh active Pending
- 2021-03-16 US US17/906,385 patent/US20230146680A1/en active Pending
- 2021-03-16 IL IL296558A patent/IL296558A/en unknown
- 2021-03-16 AU AU2021238506A patent/AU2021238506A1/en active Pending
- 2021-03-16 WO PCT/CA2021/050351 patent/WO2021184116A1/en unknown
- 2021-03-16 MX MX2022011489A patent/MX2022011489A/es unknown
- 2021-03-16 CA CA3171694A patent/CA3171694C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3171694C (en) | 2024-06-11 |
| CN115297871A (zh) | 2022-11-04 |
| JP2023518085A (ja) | 2023-04-27 |
| CA3076046A1 (en) | 2021-09-17 |
| AU2021238506A1 (en) | 2022-10-13 |
| US20230146680A1 (en) | 2023-05-11 |
| IL296558A (en) | 2022-11-01 |
| EP4121067A4 (en) | 2024-06-26 |
| EP4121067A1 (en) | 2023-01-25 |
| CA3171694A1 (en) | 2021-09-23 |
| WO2021184116A1 (en) | 2021-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2546224A (en) | Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid | |
| Dall'Amico et al. | Successful treatment of recurrent rejection in renal transplant patients with photopheresis. | |
| JP2020152698A (ja) | 間葉系幹細胞のエキソソームおよびその使用 | |
| JP6622189B2 (ja) | 疼痛及び／又は線維症の調節において脂肪組織由来細胞を使用する方法 | |
| US20090246181A1 (en) | Therapeutic composition for atopic dermatitis | |
| WO2011047345A2 (en) | Methods of treating diseases of conditions using mesenchymal stem cells | |
| MX2022011489A (es) | Metodo para producir agentes antiinflamatorios/anticatabolicos mejorados a partir de fluido fisiologico autologo. | |
| Stahl et al. | High protein intake stimulates glomerular prostaglandin formation in remnant kidneys | |
| JP2020519645A (ja) | 脂肪組織由来幹細胞による多発性硬化症の治療 | |
| JP2023521064A (ja) | 疼痛調節因子を含む幹細胞由来エクソソーム及びその用途 | |
| JP2005515186A (ja) | ＣｌＣ−２チャンネルオープナーを含む医薬組成物 | |
| TWI823964B (zh) | 幹細胞濾液製劑及其調製方法 | |
| JPH0343279B2 (es) | ||
| JP5025045B2 (ja) | 多硫酸化多糖類によるｔｉｍｐ産生の亢進 | |
| JP2005187472A (ja) | 抗ｔｎｆ治療と組み合わせた体外フォトフェレーシス | |
| Shah et al. | Eosinophilic colitis as a complication of the hypereosinophilic syndrome. | |
| US20210077538A1 (en) | Methods and compositions for treatment of penile defects | |
| RU2698089C1 (ru) | Способ лечения пациентов со склероатрофическим лихеном вульвы в консервативной терапии | |
| JPH05503089A (ja) | 薬理学的活性物質ｂｐｃ、その製造方法及びこれを治療に使用する方法 | |
| Kshirsagar et al. | Management of vascular injury in rural setup | |
| Adam et al. | A novel treatment of knee degenerative disorders all-in-one intra-articular injection of platelet-rich plasma combined with hyaluronic acid | |
| WO2015085957A1 (zh) | 治疗骨关节炎的组合物 | |
| Parsons | Traumatic uraemia | |
| Jones et al. | Decrease in hydroxyproline excretion in a patient with Marfan's syndrome after methandrostenolone therapy | |
| Ortiz et al. | Harnessing the human mesenchymal stem cells (hMSCs) secretome to couple the RV/PA during pulmonary fibrosis (PF) |